The increasing prevalence of primary “cutaneous B-cell lymphomas” is a key factor expected to aid growth of the global cutaneous B-cell lymphoma treatment market, says Fortune Business Insights in a report, titled “Cutaneous B-cell Lymphoma Treatment Market Size, Share & Industry Analysis, By Type (Radiation Therapy, Chemotherapy, Monoclonal Antibodies, Others (Corticosteroids, Interferons, etc.)), By End-user (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2019-2026.” Increasing R&D investments for the development of novel products is expected to contribute significantly to market.
As per the report, the increasing prevalence of non-Hodgkin lymphoma (NHL) is expected to propel the growth of the cutaneous B-cell lymphoma treatment market. For instance, according to an article published by NCBI in 2015, approximately 10 cases per million people every year suffer from primary cutaneous lymphomas (PCL), out of which 20-30% are primary cutaneous B-cell lymphomas (PCBCL), primary cutaneous lymphomas (PCL) are the most recurrent extra-nodal lymphomas.
The report is dedicated to offering key insights into the prevailing cutaneous B-cell lymphoma treatment market trends. It contains valuable information on market drivers, market restraints and several other aspects impacting growth witnessed in the market. It also offers recommendations to help companies determine their growth strategies.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Increasing Prevalence Of Primary Cutaneous B-Cell Lymphomas Will Encourage Growth
The increasing prevalence of primary cutaneous B-cell lymphomas is expected to fuel demand the treatment, which, will, in, turn aid expansion of the cutaneous B-cell lymphoma treatment market size. The FDA approval for polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) is expected to boost the global market. For instance, Genentech, Inc. received Food and Drug Administration approval for polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.), a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Moreover, product approvals and ongoing trials for the treatment of B-cell lymphoma in developed and developing countries is expected to further accelerate the pace growth of the market. For instance, Kite Pharma reported findings from two new analyses from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.
Furthermore, increasing research and development investments in the development of the novel products totreat cutaneous B-cell lymphoma will enable growth in the market during the forecast period. However, the lack of approved drugs for the treatment of cutaneous b-cell lymphoma, and the high cost of the treatment will hamper the growth of the global cutaneous B-cell lymphoma treatment market
Rising R&D Investments Will Aid Growth In Asia Pacific
Geographically, the global cutaneous B-cell lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 and is expected to dominate during the forecast period owing to the rising cases of primary cutaneous B-cell lymphomas. Asia Pacific is predicted to grow at a significant CAGR during the forecast period owing to the increasing research and development investments by key market players for the treatment of cutaneous B-cell lymphoma. Latin America and Middle East and Africa account for relatively lower shares and are expected to grow at a comparatively lower CAGR during the forecast period.
The Major Companies Covered In The Global Cutaneous B-Cell Lymphoma Treatment Market Report Include:
- Kite Pharma
- Genentech, Inc.
- Novartis AG
- Epizyme, Inc.
- NanoString Technologies, Inc.
- Amgen Inc.
- Johnson & Johnson Services, Inc.
and other players.